UPDATE: Citigroup Reiterates on Celgene Following Detailed Analysis
December 06, 2013 at 10:27 AM EST
In a report published Friday, Citigroup analyst Yaron Werber reiterated a Buy rating on Celgene (NASDAQ: CELG ), and raised the price target from $182.00 to $204.00. In the report, Citigroup noted, “We conducted a detailed analysis and our key takeaway is that Revlimid/dex is set to dominate the myeloma
